{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:09:57Z","timestamp":1781168997162,"version":"3.54.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Scand J Trauma Resusc Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Swift reversal of oral anticoagulation is deemed essential for the outcome of patients with anticoagulation-related critical bleeding. The aim of this systematic review was to evaluate the benefits and harms of prothrombin complex concentrate (PCC) in patients with oral anticoagulants-related critical bleeding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>For this systematic review CENTRAL, MEDLINE, Embase, LILACS, BIOSIS, Web of Science, and clinical trial registries were systematically searched. Clinical study reports were also requested from competent authorities. Eligible for inclusion were randomised clinical trials comparing PCC versus no intervention, placebo, or other reversal interventions in participants with critical bleeding related to ongoing treatment with vitamin K antagonist (VKA) or direct oral anticoagulants (DOAC). Pre-specified primary outcomes were all-cause mortality, health-related quality of life, and serious adverse events for which meta-analyses, Trial Sequential Analysis, and GRADE assessments were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Three trials, randomising a total of 291 participants, evaluated PCC against two different active comparators in participants with VKA-related critical bleeding, and two trials, randomising a total of 534 participants, evaluated PCC against two different active comparators in participants with factor Xa-related critical bleeding. Among participants with VKA-related critical bleeding, meta-analyses showed no evidence of a difference between PCC versus fresh frozen plasma (FFP) when assessing all-cause mortality (risk ratio [RR] 1.05; 95% confidence interval (CI) 0.27 to 4.05; low certainty), health-related quality of life (mean difference 1.04; 95% CI \u2212\u20090.94 to 3.02; very low certainty), and serious adverse events (RR 1.33; 95% CI 0.94 to 1.88; very low certainty), but information is currently sparse. Among participants with factor Xa-related critical bleeding, PCC could not be shown superior or inferior to other reversal strategies (FFP or andexanet alfa) on any patient-relevant outcome, but information is currently sparse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Among participants with VKA or DOAC-related critical bleeding, evidence from randomised clinical trials is currently insufficient to establish if PCC is superior or inferior versus other interventions in decreasing the risk of undesirable patient-relevant outcomes or improving health-related quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13049-025-01334-1","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:16:10Z","timestamp":1738646170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prothrombin complex concentrate for reversal of oral anticoagulants in patients with oral anticoagulation-related critical bleeding: a systematic review of randomised clinical trials"],"prefix":"10.1186","volume":"33","author":[{"given":"Christian","family":"Ovesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Purrucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Grundtvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theis Bech","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"1334_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","volume":"103","author":"AJ Camm","year":"2017","unstructured":"Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103:307\u201314.","journal-title":"Heart"},{"key":"1334_CR2","doi-asserted-by":"publisher","first-page":"e026645","DOI":"10.1136\/bmjopen-2018-026645","volume":"9","author":"G Maura","year":"2019","unstructured":"Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011\u20132016. BMJ Open. 2019;9:e026645.","journal-title":"BMJ Open"},{"key":"1334_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","volume":"194","author":"BA Steinberg","year":"2017","unstructured":"Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132\u201340.","journal-title":"Am Heart J"},{"key":"1334_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1136\/heartjnl-2016-309402","volume":"102","author":"K Adelborg","year":"2016","unstructured":"Adelborg K, Grove EL, Sundboll J, Laursen M, Schmidt M. Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. Heart. 2016;102:1883\u20139.","journal-title":"Heart"},{"key":"1334_CR5","doi-asserted-by":"publisher","first-page":"e2242964","DOI":"10.1001\/jamanetworkopen.2022.42964","volume":"5","author":"D Ko","year":"2022","unstructured":"Ko D, Lin KJ, Bessette LG, Lee SB, Walkey AJ, Cheng S, et al. Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010\u20132020. JAMA Netw Open. 2022;5:e2242964.","journal-title":"JAMA Netw Open"},{"key":"1334_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1747-4949.2011.00739.x","volume":"7","author":"HC Diener","year":"2012","unstructured":"Diener HC, Eikelboom J, Granger CB, Hacke W. The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? Int J Stroke. 2012;7:139\u201341.","journal-title":"Int J Stroke"},{"key":"1334_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"1334_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ijcard.2014.11.101","volume":"179","author":"P Sardar","year":"2015","unstructured":"Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol. 2015;179:279\u201387.","journal-title":"Int J Cardiol"},{"key":"1334_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","volume":"5","author":"JP Bassand","year":"2021","unstructured":"Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021;5:1081\u201391.","journal-title":"Blood Adv"},{"key":"1334_CR10","doi-asserted-by":"publisher","first-page":"i3189","DOI":"10.1136\/bmj.i3189","volume":"353","author":"TB Larsen","year":"2016","unstructured":"Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.","journal-title":"BMJ"},{"key":"1334_CR11","doi-asserted-by":"publisher","first-page":"j510","DOI":"10.1136\/bmj.j510","volume":"356","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.","journal-title":"BMJ"},{"key":"1334_CR12","doi-asserted-by":"publisher","first-page":"k2505","DOI":"10.1136\/bmj.k2505","volume":"362","author":"Y Vinogradova","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505.","journal-title":"BMJ"},{"key":"1334_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003725","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Fernanda Bellolio M, McBane RD, Shah ND, Noseworthy PA. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016. https:\/\/doi.org\/10.1161\/JAHA.116.003725.","journal-title":"J Am Heart Assoc"},{"key":"1334_CR14","first-page":"149","volume":"8","author":"M Franchini","year":"2010","unstructured":"Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8:149\u201354.","journal-title":"Blood Transfus"},{"key":"1334_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0140-6736(07)61199-4","volume":"370","author":"NS Key","year":"2007","unstructured":"Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370:439\u201348.","journal-title":"Lancet"},{"issue":"4","key":"1334_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2396987319849763","volume":"4","author":"H Christensen","year":"2019","unstructured":"Christensen H, Cordonnier C, K\u00f5rv J, Lal A, Ovesen C, Purrucker JC, et al. European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Euro Stroke J. 2019;4(4):294\u2013306. https:\/\/doi.org\/10.1177\/2396987319849763.","journal-title":"Euro Stroke J"},{"issue":"12","key":"1334_CR17","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1097\/CCM.0000000000002057","volume":"44","author":"JA Frontera","year":"2016","unstructured":"Frontera JA, Lewin JJ, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the neurocritical care society and the society of critical care medicine. Critic Care Med. 2016;44(12):2251\u20137. https:\/\/doi.org\/10.1097\/CCM.0000000000002057.","journal-title":"Critic Care Med"},{"key":"1334_CR18","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","volume":"53","author":"SM Greenberg","year":"2022","unstructured":"Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, et al. Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American heart association\/American stroke association. Stroke. 2022;53:e282\u2013361.","journal-title":"Stroke"},{"key":"1334_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2347-3","author":"DR Spahn","year":"2019","unstructured":"Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019. https:\/\/doi.org\/10.1186\/s13054-019-2347-3.","journal-title":"Crit Care"},{"issue":"5","key":"1334_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1097\/00006123-199911000-00020","volume":"45","author":"NM Boulis","year":"1999","unstructured":"Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45(5):1113\u20139. https:\/\/doi.org\/10.1097\/00006123-199911000-00020.","journal-title":"Neurosurgery"},{"key":"1334_CR21","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","volume":"128","author":"R Sarode","year":"2013","unstructured":"Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234\u201343.","journal-title":"Circulation"},{"key":"1334_CR22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","volume":"15","author":"T Steiner","year":"2016","unstructured":"Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15:566\u201373.","journal-title":"Lancet Neurol"},{"key":"1334_CR23","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","volume":"46","author":"JC Hemphill 3rd","year":"2015","unstructured":"Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2015;46:2032\u201360.","journal-title":"Stroke"},{"key":"1334_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1265-x","author":"R Rossaint","year":"2016","unstructured":"Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fern\u00e1ndez-Mond\u00e9jar E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016. https:\/\/doi.org\/10.1186\/s13054-016-1265-x.","journal-title":"Crit Care"},{"key":"1334_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.bja.2017.11.082","volume":"120","author":"JW Eikelboom","year":"2018","unstructured":"Eikelboom JW, Kozek-Langenecker S, Exadaktylos A, Batorova A, Boda Z, Christory F, et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. Br J Anaesth. 2018;120:645\u201356.","journal-title":"Br J Anaesth"},{"key":"1334_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.5853\/jos.2018.02250","volume":"20","author":"T Steiner","year":"2018","unstructured":"Steiner T, Kohrmann M, Schellinger PD, Tsivgoulis G. Non-vitamin K oral anticoagulants associated bleeding and its antidotes. J Stroke. 2018;20:292\u2013301.","journal-title":"J Stroke"},{"key":"1334_CR27","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"1334_CR28","unstructured":"Higgins J, Green S, (eds.). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration 2011. Available from www.handbook.cochrane.org"},{"key":"1334_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13643-018-0838-y","volume":"7","author":"C Ovesen","year":"2018","unstructured":"Ovesen C, Purrucker J, Gluud C, Jakobsen JC, Christensen H, Steiner T. Prothrombin complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients associated with oral anticoagulant administration: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Syst Rev. 2018;7:169.","journal-title":"Syst Rev"},{"key":"1334_CR30","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1334_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","author":"A Lundh","year":"2017","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.MR000033.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1334_CR32","doi-asserted-by":"publisher","first-page":"j2998","DOI":"10.1136\/bmj.j2998","volume":"358","author":"TC Hoffmann","year":"2017","unstructured":"Hoffmann TC, Oxman AD, Ioannidis JP, Moher D, Lasserson TJ, Tovey DI, et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ. 2017;358:j2998.","journal-title":"BMJ"},{"key":"1334_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:120.","journal-title":"BMC Med Res Methodol"},{"key":"1334_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1334_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/sim.6383","volume":"34","author":"O Kuss","year":"2015","unstructured":"Kuss O. Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless. Stat Med. 2015;34:1097\u2013116.","journal-title":"Stat Med"},{"key":"1334_CR36","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C. User manusal for Trial Sequential Analysis (TSA): Copenhagen Trial Unit, Denmark; 2011. Available from www.ctu.dk."},{"key":"1334_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:39.","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"1334_CR38","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.7326\/0003-4819-130-12-199906150-00019","volume":"130","author":"SN Goodman","year":"1999","unstructured":"Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Internal Med. 1999;130(12):1005. https:\/\/doi.org\/10.7326\/0003-4819-130-12-199906150-00019.","journal-title":"Ann Internal Med"},{"key":"1334_CR39","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from gradepro.org."},{"key":"1334_CR40","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations: The GRADE Working Group. Available from guidelinedevelopment.org\/handbook; Updated October 2013."},{"key":"1334_CR41","doi-asserted-by":"publisher","first-page":"110093","DOI":"10.1016\/j.jclinane.2020.110093","volume":"68","author":"K Shadvar","year":"2021","unstructured":"Shadvar K, Sadaghi P, Hamishekar H, Mahmoodpoor A. Efficacy of prothrombin complex concentrate for reversal of major bleeding due to rivaroxaban: a pilot randomized controlled trial. J Clin Anesth. 2021;68:110093.","journal-title":"J Clin Anesth"},{"key":"1334_CR42","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","volume":"390","author":"SJ Connolly","year":"2024","unstructured":"Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Czlonkowska A, Lindgren AG, et al. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. 2024;390:1745\u201355.","journal-title":"N Engl J Med"},{"key":"1334_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16350","volume":"16","author":"J Savovic","year":"2012","unstructured":"Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess. 2012;16:1\u201382.","journal-title":"Health Technol Assess"},{"key":"1334_CR44","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/jama.282.8.771","volume":"282","author":"HC Bucher","year":"1999","unstructured":"Bucher HC, Guyatt GH, Cook DJ, Holbrook A, Mcalister FA. Users\u2019 guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-based medicine working group. JAMA. 1999;282:771.","journal-title":"JAMA"},{"key":"1334_CR45","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/01.STR.0000221786.81354.d6","volume":"37","author":"HB Huttner","year":"2006","unstructured":"Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465\u201370.","journal-title":"Stroke"},{"key":"1334_CR46","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jama.2015.0846","volume":"313","author":"JB Kuramatsu","year":"2015","unstructured":"Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824\u201336.","journal-title":"JAMA"},{"key":"1334_CR47","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2314741","volume":"390","author":"G Li","year":"2024","unstructured":"Li G, Lin Y, Yang J, Anderson CS, Chen C, Liu F, et al. Intensive ambulance-delivered blood-pressure reduction in hyperacute stroke. N Engl J Med. 2024;390:1862\u201372.","journal-title":"N Engl J Med"},{"key":"1334_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(23)00806-1","volume":"402","author":"L Ma","year":"2023","unstructured":"Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023;402:27\u201340.","journal-title":"Lancet"},{"issue":"96\u2013105","key":"1334_CR49","first-page":"e5","volume":"67","author":"TJ Milling Jr","year":"2016","unstructured":"Milling TJ Jr, Refaai MA, Goldstein JN, Schneider A, Omert L, Harman A, et al. Thromboembolic events after vitamin K antagonist reversal with 4-Factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med. 2016;67(96\u2013105):e5.","journal-title":"Ann Emerg Med"},{"key":"1334_CR50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/MOH.0b013e3282ef195a","volume":"14","author":"RC Skeate","year":"2007","unstructured":"Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol. 2007;14:682\u20137.","journal-title":"Curr Opin Hematol"},{"issue":"Suppl 1","key":"1334_CR51","first-page":"65S","volume":"52","author":"S Pandey","year":"2012","unstructured":"Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52(Suppl 1):65S-79S.","journal-title":"Transfusion"},{"key":"1334_CR52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/jth.13212","volume":"14","author":"AL Marshall","year":"2016","unstructured":"Marshall AL, Levine M, Howell ML, Chang Y, Riklin E, Parry BA, et al. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. J Thromb Haemost. 2016;14:324\u201330.","journal-title":"J Thromb Haemost"},{"key":"1334_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11239-017-1506-0","volume":"44","author":"MPA Brekelmans","year":"2017","unstructured":"Brekelmans MPA, Ginkel KV, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombol. 2017;44:118\u201329.","journal-title":"J Thromb Thrombol"},{"issue":"11","key":"1334_CR54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1160\/TH16-04-0266","volume":"116","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, Crowther M. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thrombo Haemost. 2016;116(11):879\u201390. https:\/\/doi.org\/10.1160\/TH16-04-0266.","journal-title":"Thrombo Haemost"},{"issue":"14","key":"1334_CR55","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s40265-019-01179-w","volume":"79","author":"R Hill","year":"2019","unstructured":"Hill R, Han TS, Lubomirova I, Math N, Bentley P, Sharma P. Prothrombin complex concentrates are superior to fresh frozen plasma for emergency reversal of vitamin K antagonists: a meta-analysis in 2606 Subjects. Drugs. 2019;79(14):1557\u201365. https:\/\/doi.org\/10.1007\/s40265-019-01179-w.","journal-title":"Drugs"},{"key":"1334_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7270","volume":"7","author":"JJ Deeks","year":"2003","unstructured":"Deeks JJ, Dinnes J, D\u2019Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:1\u2013173.","journal-title":"Health Technol Assess"},{"key":"1334_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000012.pub3","author":"J Odgaard-Jensen","year":"2011","unstructured":"Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, Sch\u00fcnemann H, et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.MR000012.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1334_CR58","doi-asserted-by":"publisher","first-page":"e2436230","DOI":"10.1001\/jamanetworkopen.2024.36230","volume":"7","author":"M Salcher-Konrad","year":"2024","unstructured":"Salcher-Konrad M, Nguyen M, Savovi\u0107 J, Higgins JPT, Naci H. Treatment effects in randomized and nonrandomized studies of pharmacological interventions: a meta-analysis. JAMA Netw Open. 2024;7:e2436230.","journal-title":"JAMA Netw Open"},{"key":"1334_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010555.pub2","author":"M Johansen","year":"2015","unstructured":"Johansen M, Wikkels\u00f8 A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD010555.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1334_CR60","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","volume":"385","author":"JN Goldstein","year":"2015","unstructured":"Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385:2077\u201387.","journal-title":"Lancet"},{"key":"1334_CR61","first-page":"877","volume":"14","author":"B Fariborz Farsad","year":"2015","unstructured":"Fariborz Farsad B, Golpira R, Najafi H, Totonchi Z, Salajegheh S, Bakhshandeh H, et al. Comparison between prothrombin complex concentrate (PCC) and fresh frozen plasma (FFP) for the urgent reversal of warfarin in patients with mechanical heart valves in a tertiary care cardiac center. Iran J Pharmaceut Res. 2015;14:877\u201385.","journal-title":"Iran J Pharmaceut Res"},{"key":"1334_CR62","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1423-0410.2010.01339.x","volume":"99","author":"R Demeyere","year":"2010","unstructured":"Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99:251\u201360.","journal-title":"Vox Sang"},{"key":"1334_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.chest.2017.02.009","volume":"152","author":"Y Xu","year":"2017","unstructured":"Xu Y, Schulman S, Dowlatshahi D, Holbrook AM, Simpson CS, Shepherd LE, et al. Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study. Chest. 2017;152:81\u201391.","journal-title":"Chest"},{"key":"1334_CR64","doi-asserted-by":"publisher","first-page":"e0137444","DOI":"10.1371\/journal.pone.0137444","volume":"10","author":"J Skaistis","year":"2015","unstructured":"Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0137444.","journal-title":"PLoS ONE"},{"key":"1334_CR65","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ana.25342","volume":"84","author":"G Tsivgoulis","year":"2018","unstructured":"Tsivgoulis G, Wilson D, Katsanos AH, Sargento-Freitas J, Marques-Matos C, Azevedo E, et al. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. Ann Neurol. 2018;84:694\u2013704.","journal-title":"Ann Neurol"},{"key":"1334_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","volume":"73","author":"JC Purrucker","year":"2016","unstructured":"Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016;73:169\u201377.","journal-title":"JAMA Neurol"},{"key":"1334_CR67","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12245-018-0215-6","volume":"11","author":"M Hoffman","year":"2018","unstructured":"Hoffman M, Goldstein JN, Levy JH. The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. Int J Emerg Med. 2018;11:55.","journal-title":"Int J Emerg Med"},{"key":"1334_CR68","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/SHK.0000000000000848","volume":"48","author":"M Honickel","year":"2017","unstructured":"Honickel M, Akman N, Grottke O. The reversal of direct oral anticoagulants in animal models. Shock. 2017;48:144\u201358.","journal-title":"Shock"},{"key":"1334_CR69","doi-asserted-by":"publisher","first-page":"e2240145","DOI":"10.1001\/jamanetworkopen.2022.40145","volume":"5","author":"R Chaudhary","year":"2022","unstructured":"Chaudhary R, Singh A, Chaudhary R, Bashline M, Houghton DE, Rabinstein A, et al. Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e2240145.","journal-title":"JAMA Netw Open"},{"key":"1334_CR70","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","volume":"77","author":"A Gomez-Outes","year":"2021","unstructured":"Gomez-Outes A, Alcubilla P, Calvo-Rojas G, Terleira-Fernandez AI, Suarez-Gea ML, Lecumberri R, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021;77:2987\u20133001.","journal-title":"J Am Coll Cardiol"},{"key":"1334_CR71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13054-024-05014-x","volume":"28","author":"D Orso","year":"2024","unstructured":"Orso D, Fonda F, Brussa A, Comisso I, Auci E, Sartori M, et al. Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis. Crit Care. 2024;28:221.","journal-title":"Crit Care"},{"key":"1334_CR72","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","volume":"76","author":"GF Tomaselli","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76:594\u2013622.","journal-title":"J Am Coll Cardiol"},{"key":"1334_CR73","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. European heart rhythm association pactical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23:1612\u201376.","journal-title":"Europace"},{"key":"1334_CR74","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal\u2014full cohort analysis. N Engl J Med. 2017;377:431\u201341.","journal-title":"N Engl J Med"}],"container-title":["Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13049-025-01334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13049-025-01334-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13049-025-01334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:18:15Z","timestamp":1738646295000},"score":1,"resource":{"primary":{"URL":"https:\/\/sjtrem.biomedcentral.com\/articles\/10.1186\/s13049-025-01334-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1334"],"URL":"https:\/\/doi.org\/10.1186\/s13049-025-01334-1","relation":{},"ISSN":["1757-7241"],"issn-type":[{"value":"1757-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HC is a steering committee member and co-author of the ANNEXA-I trial (NCT03661528), sponsored by AstraZeneca (All honoraria received by institution). JP has received consultation fees and travel expenses from Abbott, Akcea, Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer\u2014all outside the submitted work. All remaining authors report no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}